Quidel Posts Net Loss Of $2.8 Million For Q1 2009
First Quarter 2009: Gross margin was 50.1% versus 65.4% in the first quarter of 2008 Operating expenses were $13.1 million versus $13.2 million in the same period in
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.